Lorenzo RB, Lorenzo LS, González-Martín A. Will the carboplatin-paclitaxel-bevacizumab combination become the preferred option as the first line in advanced cervical cancer? A small experience from a single oncologic Center:  . CBN [Internet]. 2017 Apr. 15 [cited 2024 Nov. 22];5(1):21-4. Available from: https://journals.aboutscience.eu/index.php/cancerbreakingnews/article/view/171